<!DOCTYPE html SYSTEM "about:legacy-compat"><html lang="en-US" data-colors-preset="contrast" data-primary-color="#307FFF"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="UTF-8"><meta name="robots" content="noindex">  <meta name="built-on" content="2024-01-01T12:25:15.0885112"><meta name="build-number" content="${buildNumber}">       <title>双鹭药业：公司在研项目GLP-1受体激动剂（日制剂）目前已完成三期所有入组受试者的随访 | 20231016</title><script id="virtual-toc-data" type="application/json">[]</script><script id="topic-shortcuts" type="application/json"></script><link href="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.css" rel="stylesheet">   <link rel="apple-touch-icon" sizes="180x180" href="https://jetbrains.com/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="https://jetbrains.com/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="https://jetbrains.com/favicon-16x16.png"><link rel="manifest" href="https://jetbrains.com/site.webmanifest"><link rel="mask-icon" href="https://jetbrains.com/safari-pinned-tab.svg" color="#000000"><meta name="msapplication-TileColor" content="#000000"/><meta name="msapplication-TileImage" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-144x144.png"/><meta name="msapplication-square70x70logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-70x70.png"/><meta name="msapplication-square150x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-150x150.png"/><meta name="msapplication-wide310x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x150.png"/><meta name="msapplication-square310x310logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x310.png"/>  <meta name="image" content=""><!-- Open Graph --><meta property="og:title" content="双鹭药业：公司在研项目GLP-1受体激动剂（日制剂）目前已完成三期所有入组受试者的随访 | 20231016"/><meta property="og:description" content=""/><meta property="og:image" content=""/><meta property="og:site_name" content="20231016 Help"/><meta property="og:type" content="website"/><meta property="og:locale" content="en_US"/><meta property="og:url" content="2455.html"/><!-- End Open Graph --><!-- Twitter Card --><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content=""><meta name="twitter:title" content="双鹭药业：公司在研项目GLP-1受体激动剂（日制剂）目前已完成三期所有入组受试者的随访 | 20231016"><meta name="twitter:description" content=""><meta name="twitter:creator" content=""><meta name="twitter:image:src" content=""><!-- End Twitter Card --><!-- Schema.org WebPage --><script type="application/ld+json"> { "@context": "http://schema.org", "@type": "WebPage", "@id": "2455.html#webpage", "url": "2455.html", "name": "双鹭药业：公司在研项目GLP-1受体激动剂（日制剂）目前已完成三期所有入组受试者的随访 | 20231016", "description": "", "image": "", "inLanguage":"en-US" }</script><!-- End Schema.org --><!-- Schema.org WebSite --><script type="application/ld+json"> { "@type": "WebSite", "@id": "/#website", "url": "/", "name": "20231016 Help" }</script><!-- End Schema.org --></head>      <body data-id="2455" data-main-title="双鹭药业：公司在研项目GLP-1受体激动剂（日制剂）目前已完成三期所有入组受试者的随访" data-article-props="{&quot;seeAlsoStyle&quot;:&quot;links&quot;}"  data-template="article"  data-breadcrumbs=""  >   <div class="wrapper"><main class="panel _main"><header class="panel__header"><div class="container"><h3>20231016  Help</h3><div class="panel-trigger"></div></div></header><section class="panel__content"><div class="container"><article class="article" data-shortcut-switcher="inactive"><h1 data-toc="2455"   id="2455.md">双鹭药业：公司在研项目GLP-1受体激动剂（日制剂）目前已完成三期所有入组受试者的随访</h1>  <p id="a6c48bf9_15"><span class="control" id="a6c48bf9_16">2023-10-16 10:12</span></p><p id="a6c48bf9_17"><span class="control" id="a6c48bf9_18">https://api3.cls.cn/share/article/1486397?os=web&amp;sv=7.7.5&amp;app=CailianpressWeb</span></p><p id="a6c48bf9_19">【双鹭药业：公司在研项目GLP-1受体激动剂（日制剂）目前已完成三期所有入组受试者的随访】财联社10月16日电，双鹭药业发布异动公告，公司在研项目GLP-1受体激动剂（日制剂）目前已完成三期所有入组受试者的随访，正处于临床数据整理阶段，初步结果显示我司研发产品和原研药诺和力&reg;疗效基本一致，安全性无差异。该产品未单独进行减肥临床研究，但在Ⅲ期临床研究中将基线和24周后的体重变化作为次要疗效指标观察。</p><div class="last-modified"> Last modified: 01 一月 2024</div><div data-feedback-placeholder="true"></div><div class="navigation-links _bottom">  <a class="navigation-links__prev" href="2459.html">国金证券公募牌照申请材料获证监会接收 有望实现&ldquo; 一控一牌&rdquo;</a>   <a class="navigation-links__next" href="2454.html">海天味业：董事长提议以5亿元至8亿元回购公司股份</a>  </div></article><div id="disqus_thread"></div></div></section></main></div>  <script src="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.js"></script></body></html>